Vestmark Advisory Solutions Inc. Buys 10,308 Shares of Sanofi (NASDAQ:SNY)

Vestmark Advisory Solutions Inc. grew its stake in Sanofi (NASDAQ:SNY) by 41.6% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 35,088 shares of the company’s stock after acquiring an additional 10,308 shares during the quarter. Vestmark Advisory Solutions Inc.’s holdings in Sanofi were worth $1,692,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the company. Farther Finance Advisors LLC grew its position in shares of Sanofi by 12.1% in the 3rd quarter. Farther Finance Advisors LLC now owns 2,861 shares of the company’s stock valued at $165,000 after purchasing an additional 309 shares during the period. Concurrent Investment Advisors LLC lifted its stake in Sanofi by 5.4% in the third quarter. Concurrent Investment Advisors LLC now owns 36,973 shares of the company’s stock valued at $2,131,000 after buying an additional 1,883 shares in the last quarter. Sittner & Nelson LLC boosted its holdings in shares of Sanofi by 566.7% in the third quarter. Sittner & Nelson LLC now owns 2,000 shares of the company’s stock valued at $115,000 after buying an additional 1,700 shares during the period. Verdence Capital Advisors LLC increased its position in shares of Sanofi by 2.6% during the third quarter. Verdence Capital Advisors LLC now owns 30,523 shares of the company’s stock worth $1,759,000 after acquiring an additional 764 shares in the last quarter. Finally, Assetmark Inc. raised its holdings in shares of Sanofi by 9.8% during the third quarter. Assetmark Inc. now owns 109,375 shares of the company’s stock worth $6,303,000 after acquiring an additional 9,787 shares during the period. 14.04% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on SNY shares. Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a “sell” rating to a “hold” rating in a research note on Thursday, January 30th. Sanford C. Bernstein raised Sanofi to a “strong-buy” rating in a research report on Thursday, January 30th. Finally, StockNews.com lowered Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. Two equities research analysts have rated the stock with a hold rating, one has given a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $60.00.

Sanofi Stock Down 0.3 %

Sanofi stock opened at $59.25 on Friday. The company has a fifty day simple moving average of $52.44 and a 200 day simple moving average of $52.73. The company has a current ratio of 1.46, a quick ratio of 1.14 and a debt-to-equity ratio of 0.15. Sanofi has a 1-year low of $45.22 and a 1-year high of $59.72. The company has a market cap of $150.37 billion, a P/E ratio of 23.80, a price-to-earnings-growth ratio of 1.01 and a beta of 0.58.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings data on Thursday, January 30th. The company reported $0.70 earnings per share for the quarter, meeting the consensus estimate of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. Research analysts anticipate that Sanofi will post 4.36 earnings per share for the current fiscal year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.